European Journal of Pharmacology 2006-07-01

Effects of NO-1886 on inflammation-associated cytokines in high-fat/high-sucrose/high-cholesterol diet-fed miniature pigs.

Manbo Cai, Weidong Yin, Qinkai Li, Duanfang Liao, Kazuhiko Tsutsumi, Hongjie Hou, Yi Liu, Chi Zhang, Jianjun Li, Zongbao Wang, Junxia Xiao

Index: Eur. J. Pharmacol. 540(1-3) , 139-46, (2006)

Full Text: HTML

Abstract

Inflammation, closely associated with obesity, is emerging as an important risk factor for the pathophysiological development of atherosclerosis and diabetes mellitus. Fat balance is critical in the aetiology of obesity. Lipoprotein lipase is an important enzyme in lipid metabolism. The aim of this study was to investigate the long-term effect of the lipoprotein lipase activator, NO-1886, on inflammation cytokines, adiposity and related diseases in miniature pigs fed a high-fat/high-sucrose/high-cholesterol diet (HFSC diet). Chinese Bama-miniature pigs were fed a control diet or HFSC diet with or without NO-1886 for 5 months. The levels of inflammation-associated cytokines were determined using the antibody arrays. Feeding of the HFSC diet to miniature pigs markedly increased the expression of inflammatory cytokines. On the other hand, supplementation of NO-1886 to HFSC diet decreased the expression of inflammatory cytokines significantly, protecting against the development of atherosclerosis and diabetes mellitus. NO-1886 may have a beneficial effect on the most inflammation-associated cytokines, and this effect may contribute to improving atherosclerosis and diabetes mellitus.


Related Compounds

Related Articles:

NO-1886 suppresses diet-induced insulin resistance and cholesterol accumulation through STAT5-dependent upregulation of IGF1 and CYP7A1.

2010-01-01

[J. Endocrinol. 1st ed., 204 , 47-56, (2010)]

Evaluation of induction potency of new drug candidates on CYP1A2 and CYP3A4 using real-time one-step RT-PCR in primary cultures of cryopreserved human hepatocytes.

2009-01-01

[Drug Metab. Pharmacokinet. 24(5) , 446-50, (2009)]

NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats.

2006-02-01

[Metab. Clin. Exp. 55(2) , 151-8, (2006)]

NO-1886, a lipoprotein lipase activator, attenuates vascular smooth muscle contraction in rat aorta.

2007-01-12

[Eur. J. Pharmacol. 554(2-3) , 183-90, (2007)]

NO-1886 ameliorates glycogen metabolism in insulin-resistant HepG2 cells by GSK-3β signalling.

2012-02-01

[J. Pharm. Pharmacol. 64(2) , 293-301, (2012)]

More Articles...